这些转移性癌细胞比那些非转移性的细胞更加易于迁移，但我们对于迁移如何进行还所知甚少。
These metastatic cells tend to move more than their non-metastatic variants but this movement is poorly understood.
在缺乏这些相互作用时转移性乳腺癌细胞应能生存。
Metastatic breast cancer cells must survive in the absence of these interactions.
结论：这些结果证实了：KRAS突变对于转移性CRC患者使用西妥昔单抗治疗时对西妥昔单抗耐药情况和生存期具有很高的预测价值。
Conclusion: These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetuximab.
应用推荐